Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes

Leuk Res. 2011 Nov;35(11):1453-6. doi: 10.1016/j.leukres.2011.07.028. Epub 2011 Aug 17.

Abstract

Considering current reliance on cancer registry data, we sought to assess the potential for bias in myelodysplastic syndrome (MDS) registration using SEER-Medicare data 2001-2005. Using a validated claims-based algorithm, we identified and compared registered and non-registered MDS patients, and found that median cumulative survival was 18 and 28 months, 74% and 64% used erythropoiesis-stimulating agents (ESAs), and average 6-month health care cost was $24,249 and $21,750, respectively. While most non-registered MDS patients showed resource utilization and survival characteristics consistent with lower-risk MDS, a subset was registered as acute myeloid leukemia (7.6%) and accounted for early mortality.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Aged, 80 and over
  • Diagnostic Tests, Routine / economics*
  • Female
  • Health Care Costs*
  • Hematinics / economics
  • Hematinics / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / economics
  • Leukemia, Myeloid, Acute / mortality
  • Male
  • Medicare / economics*
  • Myelodysplastic Syndromes / diagnosis
  • Myelodysplastic Syndromes / drug therapy
  • Myelodysplastic Syndromes / economics*
  • Myelodysplastic Syndromes / mortality*
  • Retrospective Studies
  • SEER Program
  • Survival Rate
  • United States

Substances

  • Hematinics